Artizan Biosciences reports that it has selected its lead product candidate, ARZC-001, for the treatment of inflammatory bowel disease.
The New Haven-based biotechnology company describes the candidate as a novel, oral, gut-restricted potent small-molecule inhibitor. It is designed to neutralize a specific secreted factor of microbial-driven dysregulation and inflammation in the intestine.